Spinosad - ParaPRO

Drug Profile

Spinosad - ParaPRO

Alternative Names: LY-232105; Natroba; NatrOVA creme rinse 1%; PP-105; XDE-105

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer ParaPRO
  • Class Antiparasitics; Macrolides
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pediculosis
  • Phase III Scabies

Most Recent Events

  • 10 May 2017 ParaPRO initiates enrolment in a phase III trials in Scabies (In children, In adolescents, In adults, In the elderly) in USA (Topical) (NCT02485704)
  • 02 May 2017 Phase-III clinical trials in Scabies (In children, In adolescents, In adults, In the elderly) in USA (Topical) (NCT02485717)
  • 10 Mar 2017 ParaPRO plans a phase III trial for Scabies (In children, In adolescents, In adults) in USA (NCT02485704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top